{"nctId":"NCT01796301","briefTitle":"An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women","startDateStruct":{"date":"2013-01-31","type":"ACTUAL"},"conditions":["Postmenopausal Osteoporosis"],"count":436,"armGroups":[{"label":"Romosozumab","type":"EXPERIMENTAL","interventionNames":["Drug: Romozosumab"]},{"label":"Teriparatide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Teriparatide"]}],"interventions":[{"name":"Romozosumab","otherNames":["AMG 785"]},{"name":"Teriparatide","otherNames":["Forteo","Forsteo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Postmenopausal women, aged ≥ 55 to ≤ 90.\n* Received oral bisphosphonate therapy for at least 3 years immediately prior to screening\n* BMD T-score ≤ -2.50 at the lumbar spine, total hip or femoral neck\n* History of nonvertebral fracture after age 50, or vertebral fracture.\n\nExclusion Criteria:\n\n* Use of other agents affecting bone metabolism including Strontium ranelate, fluoride (for osteoporosis), odanacatib (MK-0822) or any other cathepsin K inhibitor, IV bisphosphonates, denosumab, teriparatide (TPTD) or any parathyroid hormone (PTH) analogs, Systemic oral or transdermal estrogen, selective estrogen receptor modulators (SERMs), activated vitamin D3, vitamin K2, calcitonin, tibolone, cinacalcet, systemic glucocorticosteroids:\n* History of metabolic or bone disease (except osteoporosis) that may interfere with the interpretation of study results, such as sclerosteosis, Paget's disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome.\n* Vitamin D insufficiency, defined as 25 (OH) vitamin D levels \\< 20 ng/mL, as determined by the central laboratory.\n* Current hyper- or hypocalcemia\n* Current, uncontrolled hyper- or hypothyroidism","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"55 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD)","description":"Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA). Percent change from baseline through month 12 is the average of the treatment effect at months 6 and 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.2"},{"groupId":"OG001","value":"2.6","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Hip BMD at Month 6","description":"Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.2"},{"groupId":"OG001","value":"2.3","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Hip BMD at Month 12","description":"Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.2"},{"groupId":"OG001","value":"2.9","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Cortical BMD by Quantitative Computed Tomography (QCT) at the Total Hip at Month 6","description":"Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"0.2"},{"groupId":"OG001","value":"0.7","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Cortical BMD by QCT at the Total Hip at Month 12","description":"Cortical BMD was measured by quantitative computed tomography (QCT) at the total hip.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"0.3"},{"groupId":"OG001","value":"1.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 6","description":"Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.2"},{"groupId":"OG001","value":"2.3","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Integral BMD by QCT at the Total Hip at Month 12","description":"Integral BMD was measured by quantitative computed tomography (QCT) at the total hip.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.2"},{"groupId":"OG001","value":"3.4","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Estimated Strength at the Total Hip at Month 6","description":"Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.2"},{"groupId":"OG001","value":"2.1","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Estimated Strength at the Total Hip at Month 12","description":"Total hip estimated strength was assessed by finite element analysis (FEA) of QCT scans.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.4"},{"groupId":"OG001","value":"2.5","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 6","description":"Total hip integral BMC was measured using quantitative computed tomography (QCT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.2"},{"groupId":"OG001","value":"2.4","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Hip Integral Bone Mineral Content (BMC) by QCT at Month 12","description":"Total hip integral BMC was measured using quantitative computed tomography (QCT).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.2"},{"groupId":"OG001","value":"3.6","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Femoral Neck BMD at Month 6","description":"Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"0.3"},{"groupId":"OG001","value":"2.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Femoral Neck BMD at Month 12","description":"Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.3"},{"groupId":"OG001","value":"3.2","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lumbar Spine BMD at Month 6","description":"Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"0.3"},{"groupId":"OG001","value":"7.2","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lumbar Spine BMD at Month 12","description":"Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"0.4"},{"groupId":"OG001","value":"9.8","spread":"0.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":214},"commonTop":["Nasopharyngitis","Arthralgia","Back pain","Hypercalcaemia","Headache"]}}}